Growth Metrics

Merck (MRK) Income from Continuing Operations (2009 - 2026)

Merck (MRK) reported Income from Continuing Operations of 4209000000.0 for Q1 2026, down 182.77% year-over-year from 5085000000.0 in Q1 2025, and down 242.1% on a QoQ basis from 2962000000.0 in Q4 2025.

Merck (MRK) has 18 years of Income from Continuing Operations data on file, last reported at 4209000000.0 in Q1 2026.

  • Quarterly Income from Continuing Operations fell 182.77% year-over-year to 4209000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8968000000.0 (down 48.61% YoY) and the FY2025 annual result came in at 18263000000.0, up 6.6% from the prior year.
  • Income from Continuing Operations eased to 4209000000.0 in Q1 2026 per MRK's latest filing, from 2962000000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 5787000000.0 in Q3 2025 and bottomed at 5937000000.0 in Q2 2023.
  • The 5-year median for Income from Continuing Operations is 3744000000.0 (2024), against an average of 2713235294.12.
  • The widest annual swing landed in 2023, when Income from Continuing Operations plunged 250.34%; it then jumped 405.38% in 2024.
  • Tracing MRK's Income from Continuing Operations over 5 years: stood at 3018000000.0 in 2022, then plunged by 140.62% to 1226000000.0 in 2023, then jumped by 405.38% to 3744000000.0 in 2024, then fell by 20.89% to 2962000000.0 in 2025, then slumped by 242.1% to 4209000000.0 in 2026.
  • Per Business Quant, the three latest MRK Income from Continuing Operations figures stand at 4209000000.0 (Q1 2026), 2962000000.0 (Q4 2025), and 5787000000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 7.40 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 5.24 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 697.00 Mn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -4.21 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 1.82 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 2.02 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 2.71 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 2.68 Bn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -4.21 Bn
Dec 31, 2025 2.96 Bn
Sep 30, 2025 5.79 Bn
Jun 30, 2025 4.43 Bn
Mar 31, 2025 5.09 Bn
Dec 31, 2024 3.74 Bn
Sep 30, 2024 3.16 Bn
Jun 30, 2024 5.46 Bn
Mar 31, 2024 4.77 Bn
Dec 31, 2023 -1.23 Bn
Sep 30, 2023 4.75 Bn
Jun 30, 2023 -5.94 Bn
Mar 31, 2023 2.83 Bn
Dec 31, 2022 3.02 Bn
Sep 30, 2022 3.25 Bn
Jun 30, 2022 3.95 Bn
Mar 31, 2022 4.31 Bn
Dec 31, 2021 3.82 Bn
Sep 30, 2021 4.57 Bn
Jun 30, 2021 1.21 Bn
Mar 31, 2021 2.75 Bn
Dec 31, 2020 -2.61 Bn
Sep 30, 2020 2.33 Bn
Jun 30, 2020 2.35 Bn
Mar 31, 2020 3.22 Bn
Dec 31, 2019 -1.81 Bn
Sep 30, 2019 1.91 Bn
Jun 30, 2019 2.64 Bn
Mar 31, 2019 2.86 Bn
Dec 31, 2018 1.78 Bn
Sep 30, 2018 1.96 Bn
Jun 30, 2018 1.72 Bn
Mar 31, 2018 741.00 Mn
Dec 31, 2017 -1.04 Bn
Sep 30, 2017 -51.00 Mn
Jun 30, 2017 1.95 Bn
Mar 31, 2017 1.56 Bn
Dec 31, 2016 -587.00 Mn
Sep 30, 2016 2.19 Bn
Jun 30, 2016 1.21 Bn
Mar 31, 2016 1.13 Bn
Dec 31, 2015 982.00 Mn
Sep 30, 2015 1.83 Bn
Jun 30, 2015 688.00 Mn
Mar 31, 2015 958.00 Mn
Dec 31, 2014 7.33 Bn
Sep 30, 2014 842.00 Mn
Jun 30, 2014 2.03 Bn
Mar 31, 2014 1.73 Bn
Dec 31, 2013 815.00 Mn
Sep 30, 2013 1.15 Bn
Jun 30, 2013 935.00 Mn
Mar 31, 2013 1.62 Bn
Dec 31, 2012 949.00 Mn
Sep 30, 2012 1.76 Bn
Jun 30, 2012 1.82 Bn
Mar 31, 2012 1.77 Bn
Dec 31, 2011 1.54 Bn
Sep 30, 2011 1.72 Bn
Jun 30, 2011 2.05 Bn
Mar 31, 2011 1.07 Bn
Dec 31, 2010 -1.65 Bn
Sep 30, 2010 372.00 Mn
Jun 30, 2010 780.00 Mn
Mar 31, 2010 359.00 Mn
Dec 31, 2009 13.03 Bn
Sep 30, 2009 -1.01 Bn
Jun 30, 2009 394.00 Mn
Mar 31, 2009 802.80 Mn